UBS analyst Matthew Weston downgraded Sanofi (SNY) to Neutral from Buy with a price target of EUR 88, down from EUR 105. The firm says the company’s “failure to address pipeline replacement power is too great a strategic risk.” It also sees less buyback potential for Sanofi, with the company likely having to focus on acquisitions.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- White House releases details on Trump ‘Great Healthcare Plan’
- Sanofi’s Teplizumab Study Tracks Real-World Impact in Early Type 1 Diabetes
- Sanofi and Regeneron Withdraw Pediatric Dupilumab Growth Study: What Investors Should Know
- Street sees buying opportunity as Disc Medicine slips on FDA review delay
- Sanofi prepping higher bid for Ocular Therapeutix, IBD reports